Neximmune Valuation
| NEXIDelisted Stock | USD 2.43 0.22 9.95% |
Based on Macroaxis valuation methodology, the firm appears to be fairly valued. Neximmune secures a last-minute Real Value of $2.35 per share. The latest price of the firm is $2.43. Our model forecasts the value of Neximmune from analyzing the firm fundamentals such as Shares Owned By Insiders of 17.00 %, current valuation of (491.95 K), and Return On Equity of -1.96 as well as examining its technical indicators and probability of bankruptcy.
Fairly Valued
Today
Please note that Neximmune's price fluctuation is very steady at this time. Calculation of the real value of Neximmune is based on 3 months time horizon. Increasing Neximmune's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Neximmune is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Neximmune Pink Sheet. However, Neximmune's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 2.43 | Real 2.35 | Hype 2.43 | Naive 2.54 |
The intrinsic value of Neximmune's stock can be calculated using various methods such as discounted cash flow or dividend analysis. That value may differ from its market price, which is determined by factors such as investor sentiment, market trends, headlines, and other external factors that may influence Neximmune's stock price.
Estimating the potential upside or downside of Neximmune helps investors to forecast how Neximmune pink sheet's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Neximmune more accurately as focusing exclusively on Neximmune's fundamentals will not take into account other important factors: Neximmune Total Value Analysis
Neximmune is now anticipated to have valuation of (491.95 K) with market capitalization of 3.25 M, debt of 68.81 K, and cash on hands of 53.13 M. The negative valuation of Neximmune may imply that the market is not capable to price the future growth of the company or it is pricing it at zero value. It may also suggest that takeover valuation may not have captured all of the outstanding financial obligations of the company both on and off balance sheet. Investors should vigilantly validate all of the Neximmune fundamentals.| Takeover Price | Market Cap | Debt Obligations | Cash |
(491.95 K) | 3.25 M | 68.81 K | 53.13 M |
Neximmune Asset Utilization
One of the ways to look at asset utilization of Neximmune is to check how much profit was generated for every dollar of assets it reports. Neximmune secures a negative usage of assets of -0.7 %, losing $0.006971 for each dollar of assets held by the firm. Inadequate asset utilization conveys that the company is being less effective with each dollar of assets it secures. Strictly speaking, asset utilization of Neximmune shows how discouraging it operates for each dollar spent on its assets.Neximmune Ownership Allocation
Neximmune secures 17.0 % of its outstanding shares held by insiders and 11.17 % owned by institutional investors.Neximmune Profitability Analysis
Net Loss for the year was (32.34 M) with profit before overhead, payroll, taxes, and interest of 0.About Neximmune Valuation
An absolute valuation paradigm, as applied to Neximmune Pink Sheet, attempts to find the value of Neximmune based on its fundamental and basic technical indicators. By analyzing Neximmune's financials, quarterly and monthly indicators, and their related drivers, such as dividends, operating cash flow, and various types of growth rates, we attempt to find the most accurate representation of Neximmune's intrinsic value. In some cases, mostly for established, large-cap companies, we also incorporate more traditional valuation methods such as dividend discount, discounted cash flow, or asset-based models. As compared to an absolute model, our relative valuation model uses a comparative analysis of Neximmune. We calculate exposure to Neximmune's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Neximmune's related companies.NexImmune, Inc., a clinical-stage biotechnology company, engages in developing therapies with curative potential for patients with cancer and other life-threatening immune-mediated diseases. NexImmune, Inc. was incorporated in 2011 and is headquartered in Gaithersburg, Maryland. Neximmune operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 74 people.
8 Steps to conduct Neximmune's Valuation Analysis
Company's valuation is the process of determining the worth of any company in monetary terms. It estimates Neximmune's potential worth based on factors such as financial performance, market conditions, growth prospects, and overall economic environment. The result of company valuation is a single number representing a Company's current market value. This value can be used as a benchmark for various financial transactions such as mergers and acquisitions, initial public offerings (IPOs), or private equity investments. To conduct Neximmune's valuation analysis, follow these 8 steps:- Gather financial information: Obtain Neximmune's financial statements, including balance sheets, income statements, and cash flow statements.
- Determine Neximmune's revenue streams: Identify Neximmune's primary sources of revenue, including products or services offered, target markets, and pricing strategies.
- Analyze market data: Research Neximmune's industry and market trends, including the size of the market, growth rate, and competition.
- Establish Neximmune's growth potential: Evaluate Neximmune's management, business model, and growth potential.
- Determine Neximmune's financial performance: Analyze its financial statements to assess its historical performance and future potential.
- Choose a valuation method: Consider the Company's specific circumstances and choose an appropriate valuation method, such as the discounted cash flow (DCF) or comparable analysis method.
- Calculate the value: Apply the chosen valuation method to the financial information and market data to calculate Neximmune's estimated value.
- Review and adjust: Review the results and make necessary adjustments, considering any relevant factors that may have been missed or overlooked.
Neximmune Growth Indicators
Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines.
| Common Stock Shares Outstanding | 1 M |
Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in interest. You can also try the Commodity Directory module to find actively traded commodities issued by global exchanges.
Other Consideration for investing in Neximmune Pink Sheet
If you are still planning to invest in Neximmune check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Neximmune's history and understand the potential risks before investing.
| CEOs Directory Screen CEOs from public companies around the world | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| Stocks Directory Find actively traded stocks across global markets | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. |